Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials.
BACKGROUND AND OBJECTIVE: A number of reports have been published on the possible involvement of changes in brain cholesterol metabolism in the origin of Alzheimer's disease (AD) and the potential for influencing these changes by administration of HMG-CoA reductase inhibitors ('statins'). The aim of...
| Publicado en: | Drugs & Aging Vol. 24; no. 1; pp. 57 - 62 |
|---|---|
| Autores principales: | , , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
2007
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105998041&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105998041 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1170229X C5B jtl: Drugs & Aging issn: 1170229X maglogo: N pubinfo: dt: 2007 vid: 24 iid: 1 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 105998041 2009505585 10.2165/00002512-200724010-00004 NLM17233547 105998041 ppf: 57 ppct: 5 formats: fmt: @attributes: type: P tig: atl: Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials. aug: au: Winblad B Jelic V Kershaw P Amatniek J sug: subj: Alzheimer's Disease Drug Therapy Antilipemic Agents Cognition Disorders Drug Therapy Galanthamine Therapeutic Use Nootropic Agents Therapeutic Use Aged Double-Blind Studies Drug Interactions Drug Therapy, Combination Female Male Human Aged: 65+ years Female Male ab: BACKGROUND AND OBJECTIVE: A number of reports have been published on the possible involvement of changes in brain cholesterol metabolism in the origin of Alzheimer's disease (AD) and the potential for influencing these changes by administration of HMG-CoA reductase inhibitors ('statins'). The aim of this study was to evaluate a potential association between use of statins and maintenance of cognitive function in patients with AD in galantamine clinical trials. METHOD: A posthoc analysis was conducted on data pooled from three double-blind, placebo-controlled, clinical trials of galantamine in patients with AD. Patients were divided into four treatment groups: statin plus galantamine (n = 42), statin alone (n = 50), galantamine alone (n = 614) or neither galantamine nor statin (n = 619). RESULTS: Galantamine was associated with a significant beneficial effect on cognitive status (p < 0.001). The association of use of statins with changes in cognitive status was not significant (p = 0.083). There was no significant interaction between the effects on cognition of statins and galantamine (p = 0.183) and no statistically significant changes in adverse effect rates were observed. CONCLUSION: These findings suggest the need for larger long-term trials to confirm or refute possible effects of statins on cognitive function and the potential interaction of statins with acetylcholinesterase inhibitors in the treatment of AD. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|